Gregory Poch
Overview
Explore the profile of Gregory Poch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adjei A, Cohen R, Franklin W, Morris C, Wilson D, Molina J, et al.
J Clin Oncol
. 2008 Apr;
26(13):2139-46.
PMID: 18390968
Purpose: To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer. Patients And Methods: In...
2.
Le Huerou Y, Gunawardana I, Thomas A, Boyd S, De Meese J, DeWolf W, et al.
Bioorg Med Chem Lett
. 2007 Dec;
18(2):505-8.
PMID: 18083562
Transketolase, a key enzyme in the pentose phosphate pathway, has been suggested as a target for inhibition in the treatment of cancer. Compound 5a ('N3'-pyridyl thiamine'; 3-(6-methyl-2-amino-pyridin-3-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium chloride hydrochloride), an...
3.
Wallace E, Lyssikatos J, Blake J, Seo J, Yang H, Yeh T, et al.
J Med Chem
. 2006 Jan;
49(2):441-4.
PMID: 16420026
The role of MEK 1,2 in cancer tumorgenesis has been clearly demonstrated preclinically, and two selective inhibitors are currently undergoing clinical evaluation to determine their role in the human disease....